In the newest @MakingMedPod, @johnbstanford breaks down the biggest biotech stories of 2025 -- from national security priorities and venture funding shifts to AI-driven drug development, FDA approvals, and PBM reform efforts. Full episode on YouTube: youtube.com/watch?v=oaS0RUQ7…

🎙️ NEW: Making Medicine ft. @SenThomTillis This episode breaks down the policies shaping America’s innovation edge — with a spotlight on MFN-style price controls and what they could mean for U.S. R&D. 🇨🇳 China’s accelerating biotech competition 📜 Patent eligibility + its “dampening effect on innovation” 🌐 MFN and why foreign price benchmarks threaten future cures ⚖️ Regulatory certainty + investment 💡 How the U.S. stays ahead Watch the full convo → youtu.be/iw-Z_avXyb0?si=FVfc… 🎧 Follow @MakingMedPod for more biotech + policy insights.

HHS, FDA, and CMS leaders announced new steps this week to simplify biosimilar approvals, potentially reducing clinical testing requirements and speeding market entry for more affordable therapies. @johnbstanford covers this and more on the latest edition of @MakingMedPod:

On a new episode of @MakingMedPod, @johnbstanford shares that biotech leaders are feeling the weight of policy uncertainty, citing that "many executives and investors said what is happening in Washington makes it very, very hard to invest."

On @MakingMedPod, @johnbstanford shares what he's hearing in Boston: fewer international students, shrinking biotech pipelines, and fears of a growing "brain drain." Biotech is hard -- America needs to show young scientists that their work and talent matter here.

ICYMI: On @MakingMedPod's FDA Approvals Corner, @johnbstanford shared recent FDA approvals, celebrating important advances for patients with rare diseases and cancer. Watch here: youtube.com/watch?v=kld5KKpM…

On this week's @MakingMedPod, guest @maxonwifi warns that biotech is at a crossroads: the U.S. saw its first net loss in biotech jobs in years, while China pours resources into growing its ecosystem. Watch the full episode on YouTube.

On the latest @MakingMedPod, @maxonwifi highlights the wave of actions facing drugmakers: MFN deadlines, tariff pressures, and possible executive moves involving out-licensing from China. See the full episode on YouTube.

In the newest @MakingMedPod, Patrick Jordan likens MFN drug pricing to a mismatched organ transplant -- well-intentioned, but doomed long-term. The U.S. health care system is fundamentally different from the rest of the world, so a one-size-fits-all policy doesn't work.

Many countries set drug prices using comparators. That's like pricing a 4K smart TV the same as an old-school RCA because they're both "TVs." In @MakingMedPod, @johnbstanford unpacks the realities of importing MFN pricing. See the full episode on YouTube.

On the newest edition of @MakingMedPod, @johnbstanford covers industry headlines: Trump's pharma tariffs and drug pricing push, biotech IPOs, & NIH cuts. We also debut a new FDA Approvals corner. Watch the full episode on YouTube: youtube.com/watch?v=P6RH02eA…

On the newest @MakingMedPod, @johnbstanford sits down with @KendalleOC, @MassBIO CEO & president, to break down the MassBIO 2025 Industry Snapshot and explore how policy decisions are shaping biotech investment in Massachusetts. Full episode on YouTube: youtu.be/cvYlplqW37I?feature…